Ref ID: 17774
Author:
M.J.P. van Wanrooy*, M.G.G. Rodgers, D.R.A. Uges, J.P. Arends,
J.G. Zijlstra, T.S. van der Werf, J.G.W. Kosterink, J.W.C.
Alffenaar
Author address:
(Groningen, NL)
Full conference title:
22nd European Congress of Clinical Microbiology and Infectious Diseases
Abstract:
Objectives: Early antifungal treatment with adequate drug exposure
reduces mortality in patients with candidemia. Efficacy ofanidulafungin is driven by AUC (area under the curve)/MIC ratio. As
anidulafungin clearance is 30% higher in patients with invasive
candidiasis than in patients with oesophageal candidiasis patients at the
ICU may be at risk for underexposure. Therefore, insight in
anidulafungin pharmacokinetics in a ’’real-life’’ population of
critically ill patients is important.
Methods: We conducted a prospective open-label study in adult
patients admitted to an intensive care unit between June 2010 and
November 2011. Patients were eligible for inclusion in case of a
positive culture for Candida from a sterile site – blood or intraabdominal
fluid. Blood samples were taken just before administering
anidulafungin and at 1.5, 2, 3, 4, 6, 8, 12 and 24 hours after start of
infusion on day 3 or 4 of treatment. Anidulafungin plasma
concentrations were measured with a validated LC-MS/MS method.
The AUC was calculated using a non compartmental method.
Results: Twenty patients with a median age of 71 (IQR: 60-75) were
studied; 11 males and 9 females. Cultures for Candida were positive in
blood for seven patients and in intra-abdominal fluid for 13 patients. In
comparison with previously reported data of critically ill patients, we
observed an apparent lower exposure and clearance and longer half-life
in our patients, see Table. The volume of distribution was similar. MIC
values ranged from <0.002 to 0.02 mg/L, and AUC/MIC ratios from
3580 to 32 250. Both anidulafungin Cmax and Cmin showed a significant
correlation with the anidulafungin AUC (Cmax: R = 0.854, p < 0.001;
Cmin: R = 0.884, p < 0.001; Spearman correlation coefficient).
Abstract Number: NULL
Conference Year: 2012
Link to conference website: NULL
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Teclegiorgis Gebremariam [MS]1, Yiyou Gu [PhD]1, Sondus Alkhazraji [PhD]1, Jousha Quran1, Laura K. Najvar [BS]2, Nathan P. Wiederhold [PharmD]2, Thomas F. Patterson [MD]2, Scott G. Filler [MD]1,3, David A. Angulo (MD)4, Ashraf S. Ibrahim [PhD]1,3*,
2024
91
n/a
-
v
Ruta Petraitiene (US)
2024
90
n/a
-
v
Fabio Palmieri (CH), Junier Pilar
2024
89
n/a
-
v
Evelyne Côté (CA)
2024
88
n/a
-
v
Eliane Vanhoffelen (BE)
2024
87
n/a
-
v
Teclegiorgis Gebremariam, Yiyou Gu, Eman Youssef, Sondus Alkhazraji, Joshua Quran, Nathan P. Wiederhold, Ashraf S. Ibrahim
2024
86
n/a
-
v
Thomas Orasch (DE)
2024
85
n/a
-
v
Julien Alex, Katherine González, Gauri Gangapurwala, Antje Vollrath, Zoltán Cseresnyés, Christine Weber, Justyna A. Czaplewska, Stephanie Hoeppener, Carl-Magnus Svensson, Thomas Orasch, Thorsten Heinekamp, Carlos Guerrero-Sánchez, Marc Thilo Figge, Ulrich S. Schubert, Axel A. Brakhage
2024
84
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
83
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
82
n/a